CorMedix Reports Strong Q1 2026 Results, Raises Full-Year Revenue and EBITDA Guidance

summarizeSummary

CorMedix Inc. announced robust first-quarter 2026 financial results, significantly increasing net revenue and net income, and subsequently raised its full-year 2026 revenue and adjusted EBITDA guidance.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Net revenue surged to $127.4 million, with net income of $38.6 million and adjusted EBITDA of $70.0 million, demonstrating substantial year-over-year growth.

• Raised Full-Year 2026 Guidance

  The company increased its full-year 2026 net revenue guidance to $325-$345 million and adjusted EBITDA guidance to $115-$135 million, reflecting strong business momentum.

• DefenCath Sales Exceed Expectations

  DefenCath contributed $97.5 million in net revenue, bolstered by increased utilization and a non-recurring $9.0 million favorable change in sales allowance estimates.

• Solid Cash Position

  CorMedix reported $178.1 million in cash and short-term investments, providing over 12 months of operational funding.

auto_awesomeAnalysis

This filing is highly important as CorMedix reported exceptionally strong first-quarter financial results, significantly exceeding prior-year performance across key metrics like revenue, net income, and adjusted EBITDA. The company's decision to raise its full-year 2026 revenue and adjusted EBITDA guidance signals continued confidence in its growth trajectory, particularly driven by strong DefenCath sales and the integration of the Melinta portfolio. This positive financial update, following recent positive Phase III trial results for REZZAYO, reinforces the company's strong operational momentum and improved financial health.